drugset
drugset / Trial / NCT00685269

Safety and Efficacy of Eszopiclone With Mild to Moderate Obstructive Sleep Apnea Syndrome (OSAS)

NCT00685269 ↗

Phase 2 Completed 20 enrolled Sumitomo Pharma America, Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the hypnotic efficacy of ezopiclone in subjects with mild to moderate OSAS.

Timeline

Start
2003-08
Primary completion
2004-01
Completion
2004-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eszopiclone Small molecule 3 mg —

Indications

obstructive sleep apnea syndrome